For those interested, Zenith's ZEN003694 trial is now listed on ClinicalTrials.gov as ClinicalTrials.gov identifier NCT02705469. For those unaware, Zenith is Resverlogix's spin-off company from summer 2013 and has its own Agoracom page too.
A Phase 1 Safety and Tolerability Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer
ClinicalTrials.gov Identifier:NCT02705469
First received: February 10, 2016
Last updated: March 4, 2016
Last verified: March 2016
Estimated Enrollment: 44
Study Start Date: April 2016
Estimated Study Completion Date: April 2018
Estimated Primary Completion Date: April 2018 (Final data collection date for primary outcome measure)